CT186 / 14 - A first-in-human phase 1 dose-escalation and expansion study of intratumoral oncolytic reovirus (RC402) as a monotherapy or in combination with pembrolizumab in advanced solid tumors,
This trial is due to present at the AACR 24 in the same segment as CF33- NHIS, it's been around a while and very much a competitor,
also of interest when you look up the presentation about CF33 no Yuman or Chong on the list. P Woodard and J Byon seem the senior ones.
Clinical trial abstracts are under embargo and will be released at 3:00 PM ET on Friday, April 5.
CT186 / 14 - A first-in-human phase 1 dose-escalation and...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.1¢ |
Change
0.001(1.67%) |
Mkt cap ! $446.5M | |||
| Open | High | Low | Value | Volume |
| 6.0¢ | 6.3¢ | 5.8¢ | $1.661M | 27.74M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 513999 | 6.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.2¢ | 51941 | 2 |
View Market Depth
| Last trade - 16.10pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
6.2¢ |
Change
0.001 ( 4.38 %) |
||||
| Open | High | Low | Volume | ||
| 6.0¢ | 6.2¢ | 5.8¢ | 10422066 | ||
| Last updated 15.59pm 05/06/2024 ? | |||||
| IMU (ASX) Chart |